Shore Capital cheers Coiled Therapeutics dosing progress
Published: 23:31 21 Sep 2026 AEST
Shore Capital has welcomed the latest step forward in Coiled Therapeutics' (AIM:COIL, OTCQB:COTXF) cancer drug trial, reiterating its support for the AIM-listed group.
The broker was responding to Monday's news that Coiled had enrolled six patients across two dose groups testing a reformulated version of its lead drug, AO-252.
Analysts Sean Conroy and Brian White said the update, while light on fresh data, offered reassurance that the reformulation programme was advancing as planned.
The softgel version is designed to improve how the drug is absorbed, addressing a weakness of the earlier tablet.
Shore Capital pointed to the bigger prizes still ahead.
It expects initial safety data by the end of this year and, crucially, preliminary efficacy results in the first half of 2027.
The broker called those results an important value inflection point that could shape talks with potential pharma partners.
It highlighted the appeal of AO-252's target, a protein called TACC3 that helps tumours grow but appears less vital to healthy cells, raising the prospect of hitting cancer without heavy side effects.
The drug has already shown an 80% clinical benefit rate in heavily pre-treated patients, albeit across a small group.